Chronic cutaneous lupus erythematosus
MONDO:0015574Chronic cutaneous lupus erythematosus (CCLE) is a form of cutaneous lupus erythematosus (CLE) that includes five different forms: discoid lupus erythematosus (DLE), chilblain lupus, hypertrophic or verrucous lupus erythematosus, lupus erythematosus tumidus, and lupus erythematosus panniculitis.
Also known as: cutaneous lupus erythematosus, chronic
58 clinical trials for this condition and its sub-types, 3 tagged with Chronic cutaneous lupus erythematosus itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Chronic cutaneous lupus erythematosus
-
Discoid lupus erythematosus 17 trials
-
Lupus erythematosus tumidus 3 trials
-
Chilblain lupus 1 trial · 3 incl. sub-types
1 sub-type
- Familial chilblain lupus 2 trials Sub-types →
-
Lupus erythematosus panniculitis 0 trials
Most studied deeper sub-types
-
New hope for lupus skin lesions: drug trial targets stubborn cases
Disease control OngoingThis study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…
Phase 2/3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New shot could tame lupus skin flares
Disease control OngoingThis study tests an experimental drug called IMVT-1402 in people with lupus-related skin rashes (subacute or chronic cutaneous lupus) that haven't gotten better with standard treatments. About 56 participants will receive either the drug or a placebo for 12 weeks, then all get th…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for lupus skin sufferers: Long-Term drug trial launches
Disease control By invitation onlyThis study tests the long-term safety of the drug litifilimab in adults with lupus skin disease (CLE) that didn't improve with standard antimalarial treatment. About 322 participants who completed a prior study will receive injections every 4 weeks for up to 2 years (or 5 years i…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC